5

10

- 1. A method for identifying a compound that modulates the expression or activity of a daf-18 gene, comprising:
 - (a) providing a cell expressing a daf-18 gene; and
- (b) contacting said cell with a candidate compound, an alteration in daf-18 expression or activity following contact with said candidate compound identifying a modulatory compound.
- 2. A method for identifying a compound that modulates the expression or activity of a dalf-18 gene, comprising:
 - (a) providing a cell comprising a mutation in a daf-18 gene;
 - (b) expressing in said cell a mammalian DAF-18 homologue; and
- (c) contacting said cell with a candidate compound, an alteration in said mammalian DAF-18 expression or activity following contact with said candidate compound identifying a modulatory compound.

2. The method of claim 1 or 2, wherein said compound increases daf-18 expression or activity and is therefore capable of increasing longevity of a cell or organism.

3. The method of claim 1 or 2, wherein said compound decreases daf-18 activity and is capable of treating an impaired glucose tolerance condition or obesity.

10



4. The method of claim 1 or 2, wherein said method is carried out in a transgenic animal.

- 5. The method of claim 4, wherein said animal is a nematode.
- 6. The method of claim 4, wherein said animal is a mouse.
- 7. The method of claim 2, wherein said DAF-18 homologue is a human homologue.
 - 8. The method of claim 7, wherein said DAF-18 homologue is PTEN.
 - 9. A method for identifying a compound that is capable of ameliorating or delaying an impaired glucose tolerance condition or obesity, comprising contacting a biological sample with a candidate compound and assaying said sample for DAF-18-mediated lipid phosphatase activity, a decrease in said activity indicating a compound capable of ameliorating or delaying an impaired glucose tolerance condition or obesity.
- 10. A method for identifying a compound that is capable of increasing longevity of a cell or organism, comprising contacting a biological sample with a candidate compound and assaying said sample for DAF-18-mediated lipid phosphatase activity, an increase in said activity indicating a compound capable of increasing longevity of a cell or organism.

Ì

5

10


15

- 11. A method for identifying a compound that is capable of ameliorating or delaying an impaired glucose tolerance condition or obesity, comprising contacting a biological sample with a candidate compound and assaying said sample for PTEN-mediated lipid phosphatase activity, a decrease in said activity indicating a compound capable of ameliorating or delaying an impaired glucose tolerance condition or obesity.
- 12. A method for identifying a compound that is capable of increasing longevity of a cell or organism, comprising contacting a biological sample with a candidate compound and assaying said sample for PTEN-mediated lipid phosphatase activity, an increase in said activity indicating a compound capable of increasing longevity of a cell or organism.
- 13. The method of claim 9 or 11, wherein said method further comprises assaying said compound in a cell which comprises a mutation in a *daf-18* gene and which expresses a mammalian DAF-18 homologue, a decrease in DAF-18 activity indicating a compound capable of treating an impaired glucose tolerance condition or obesity.
- 14. The method of claim 10 or 12, wherein said method further comprises assaying said compound in a cell which comprises a mutation in a daf18 gene and which expresses a mammalian DAF-18 homologue, an increase in DAF-18 activity indicating a compound capable of increasing longevity of a cell or organism.

5

10

- 15. The method of claim 13, wherein said mammalian DAF-18 homologue is human PTEN.
- 16. The method of claim 14, wherein said mammalian DAF-18 homologue is human PTEN.
- 17. A method of diagnosing an impaired glucose tolerance condition, obesity, or a propensity thereto in a patient, said method comprising analyzing the level of PTEN expression or activity in a sample isolated from said patient, whereby an increase in said level of PTEN expression or activity relative to a control sample is an indication of an impaired glucose tolerance condition, obesity, or a propensity thereto.
 - 18. A method of diagnosing longevity in a patient, said method comprising analyzing the level of PTEN expression or activity in a sample isolated from said patient, whereby a decrease in said level of PTEN expression or activity relative to a control sample is an indication of decreased longevity.
- 19. A method of ameliorating or delaying the onset of an impaired glucose tolerance condition in a patient, said method comprising administering to said patient a therapeutically-effective amount of a compound that decreases PTEN expression or activity.
- 20. A method of increasing longevity in a patient, said method comprising administering to said patient a therapeutically-effective amount of



- 21. The method of claim 19 or 20, wherein said PTEN is human PTEN.
- 22. A transgenic non-human animal whose cells contain a transgene encoding a mammalian PTEN polypeptide.

23. The transgenic animal of claim 22, wherein said animal is a 5 nematode.

24. The transgenic animal of claim 23, wherein said animal carries a mutation in a ddf-18 gene.

957 NDD 7